<DOC>
	<DOCNO>NCT00961636</DOCNO>
	<brief_summary>This study evaluate efficacy laropiprant ( LRPT ) reduce flush symptom beyond 6 month measure impact withdrawal laropiprant patient follow 20 week stable maintenance therapy .</brief_summary>
	<brief_title>A Long-term Study ERN/LRPT ( Extended Release Niacin/Laropiprant MK0524A ) Patients With Dyslipidemia ( 0524A-102 )</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient male , female unlikely conceive , indicate meeting least one follow condition : ( ) Patient male . ( b ) Patient female reproductive potential either agree remain abstinent ( form birth control accept local regulatory agency review committee sole method birth control ) use ( partner use ) 2 acceptable method birth control within project duration study . ( c ) Patient female reproductive potential therefore eligible participate study without require use contraception . Lipidmodifying therapy ( LMT ) appropriate patient Patient meet one follow criterion base National Cholesterol Education Program Adult Treatment Panel III guideline : 1 ) High risk statin LDLcholesterol ( LDLC ) &lt; 100 mg/dL intolerant statins LDLC &lt; 120 mg/dL ; 2 ) Multiple risk LDLC &lt; 130 mg/dL ; 3 ) Low risk LDLC &lt; 190 mg/dL Patient triglyceride level &lt; 500 mg/dL Patient pregnant , breastfeeding , expect conceive Patient history cancer within 5 year screen ( except certain skin cervical cancer ) Female patient plan donate egg study Male patient plan donate sperm study Patient history condition , therapy , lab abnormality might confound study result , interfere participation full duration study , make participation study patient 's best interest Patient donate received blood within 8 week screen plan donate/receive blood 8 week study Patient experience menopausal hot flash Patient chronic heart failure , uncontrolled cardiac arrhythmia , poorly control hypertension Patient type 1 2 diabetes poorlycontrolled , newly diagnose , recently repeat hypoglycemia , take new recently adjust antidiabetic medication Patient uncontrolled metabolic endocrine disease influence serum lipid lipoproteins Patient kidney disease Patient active peptic ulcer within 3 month screen Patient history heart attack , stroke , heart bypass surgery , angina , angioplasty within 3 month screen Patient human immunodeficiency virus ( HIV ) positive Patient take take niacin &gt; 50 mg daily within 6 week screen Patient change type dose LMT regimen within 6 week Visit 1 Patient take statin fibrate screening Patient take long act nonsteroidal antiinflammatory drug ( NSAID ) , naproxen aspirin &gt; 100 mg per day screen Patient arterial bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>